Oncology Nursing News
Panelists discuss how establishing trust and open communication with patients with chronic myeloid leukemia (CML) is crucial for treatment adherence, emphasizing the importance of …
Olanzapine May Address AEs From TKIs for Kidney and Other …
Feb 17, 2025 · Olanzapine may be effective in managing adverse effects (AEs) from tyrosine-kinase inhibitors (TKIs) including vomiting, nausea, insomnia, anorexia, and weight loss, …
Oncology Drugs Approved by the FDA in January 2025
Feb 3, 2025 · Throughout the month of January, the FDA has granted approval to several therapies to treat diseases including breast cancer, mantle cell lymphoma (MCL), acute …
Osimertinib Sustains OS Improvement in EGFR-Mutant NSCLC
Mar 31, 2025 · Osimertinib (Tagrisso) displayed a sustained overall survival (OS) benefit as a monotherapy and in combination with savolitinib (Orpathys) or datopotamab deruxtecan-dlnk …
Recent and Upcoming Advances in Breast Cancer Treatment
Jan 29, 2025 · Several new treatment options for patients with breast cancer have emerged over the last few years, including more oral medications like trastuzumab deruxtecan (Enhertu) and …
Approvals in Cancer Care Call for Multidisciplinary Cooperation
Mar 17, 2025 · With new treatment options for patients with cancer, oncology nurses and APPs should be ready to educate patients and work with interdisciplinary teams to maintain care, …
FDA Approves Larotrectinib for NTRK Fusion-Positive Solid Tumors
Apr 10, 2025 · The FDA approved larotrectinib (Vitrakvi) for use in adult and pediatric patients who have neurotrophic receptor tyrosine kinase (NTRK) gene fusion-positive solid tumors and …
Understanding the Role of an Oncology Research Nurse
Sep 26, 2024 · Oncology research nurses play an integral role in collecting data and assessing for adverse events throughout a clinical trial, which, in turn, can lead to their support in the …
Managing Oncology Nurse Burnout Through Peer Support, …
Mar 28, 2025 · Having a network of support from peers is a way to prevent burnout for oncology nurses and advanced practice providers (APPs) who frequently deal with losses of patients, …
Cabozantinib Approved for Unresectable, Advanced/Metastatic …
Mar 26, 2025 · Cabozantinib received FDA approval for use in patients at least 12 years old with unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine …